Lahoud Oscar B, Sauter Craig S, Hamlin Paul A, Dahi Parastoo Bahrami
Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Curr Oncol Rep. 2015 Sep;17(9):42. doi: 10.1007/s11912-015-0465-x.
High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HDT/ASCT) can improve survival in patients with lymphoma. Limited experience is available on the safety and efficacy of HDT/ASCT in elderly patients. In this article, we review the published data on the role of HDT/ASCT in management of lymphoma in older patients. Based on available data, evaluation of comorbidities, functional status, and comprehensive geriatric assessment (CGA) will help identify those who can benefit most from this intervention. Prospective clinical trials focusing on HDT/ASCT in older patients with lymphoma are needed to establish optimal management protocols in this select population.
大剂量化疗后行自体造血干细胞移植(HDT/ASCT)可提高淋巴瘤患者的生存率。关于HDT/ASCT在老年患者中的安全性和有效性的经验有限。在本文中,我们回顾了已发表的关于HDT/ASCT在老年淋巴瘤患者治疗中作用的数据。根据现有数据,评估合并症、功能状态和综合老年评估(CGA)将有助于确定那些能从该干预措施中获益最大的患者。需要开展针对老年淋巴瘤患者HDT/ASCT的前瞻性临床试验,以制定这一特定人群的最佳治疗方案。